ES2314069T3 - Transferencia genica neuronal mejorada. - Google Patents

Transferencia genica neuronal mejorada. Download PDF

Info

Publication number
ES2314069T3
ES2314069T3 ES02743020T ES02743020T ES2314069T3 ES 2314069 T3 ES2314069 T3 ES 2314069T3 ES 02743020 T ES02743020 T ES 02743020T ES 02743020 T ES02743020 T ES 02743020T ES 2314069 T3 ES2314069 T3 ES 2314069T3
Authority
ES
Spain
Prior art keywords
vector
bont
neurons
transgene
motor neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02743020T
Other languages
English (en)
Spanish (es)
Inventor
Stephanie Millecamps-Navarro
Martine Barkats
Jacques Mallet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2314069T3 publication Critical patent/ES2314069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02743020T 2001-05-22 2002-05-15 Transferencia genica neuronal mejorada. Expired - Lifetime ES2314069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401342A EP1262188A1 (de) 2001-05-22 2001-05-22 Verbesserter neuronaler Gentransfer
EP01401342 2001-05-22

Publications (1)

Publication Number Publication Date
ES2314069T3 true ES2314069T3 (es) 2009-03-16

Family

ID=8182738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02743020T Expired - Lifetime ES2314069T3 (es) 2001-05-22 2002-05-15 Transferencia genica neuronal mejorada.

Country Status (7)

Country Link
US (1) US7341718B2 (de)
EP (2) EP1262188A1 (de)
CA (1) CA2446201C (de)
DE (1) DE60229236D1 (de)
ES (1) ES2314069T3 (de)
HK (1) HK1061351A1 (de)
WO (1) WO2002094308A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308917D0 (en) 2013-05-17 2013-07-03 Renishaw Plc Delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
WO1995022560A1 (en) * 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain

Also Published As

Publication number Publication date
EP1262188A1 (de) 2002-12-04
US20040131593A1 (en) 2004-07-08
WO2002094308A1 (en) 2002-11-28
CA2446201A1 (en) 2002-11-28
EP1390059B1 (de) 2008-10-08
DE60229236D1 (de) 2008-11-20
EP1390059A1 (de) 2004-02-25
HK1061351A1 (en) 2004-09-17
US7341718B2 (en) 2008-03-11
CA2446201C (en) 2012-07-17

Similar Documents

Publication Publication Date Title
Foust et al. Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons
Chen et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo.
US8450106B2 (en) Oncolytic virus
WO2014037881A1 (en) Compositions and methods for parkinson's disease treatment by bdnf-flag gene transfer through neurotensin polyplex to nigral dopamine neurons
Aly et al. Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain
US10059742B2 (en) Peptides and methods and uses thereof for preventing retinal disorders
CA2406233A1 (en) Compositions for drug delivery
JP2021505135A (ja) Ｃｄｋｌ５発現変異体及びｃｄｋｌ５融合タンパク質
WO2004035779A1 (ja) ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム
ES2314069T3 (es) Transferencia genica neuronal mejorada.
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
US7018628B1 (en) Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
Millecamps et al. Adenoviral retrograde gene transfer in motoneurons is greatly enhanced by prior intramuscular inoculation with botulinum toxin
US20220033450A1 (en) Virally expressed inhibitors of pdz domains, such as pick1 and uses thereof
US7273854B1 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders
CA2277869A1 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
US20020137698A1 (en) Antisense inhibition of rad51
KR100835880B1 (ko) 세포 도입성 열충격단백질 27 융합 단백질
US20030125239A1 (en) Compositions for drug delivery
C. Papadopoulos, RG Giffard, BA Bell Principles of gene therapy: potential applications in the treatment of cerebral ischaemia
Aly An Intranasal GDNF Gene Therapy Approach for Treating Parkinson's Disease
Mori et al. Intercellular trafficking activity of herpes simplex virus US11 gene product in the mouse brain
Read et al. 1334. Addition of Nuclear Localization Signal Sequences from Both the HIV-1 Matrix and the HIV-1 Vpr Proteins into a Non-Viral Gene Delivery System Produces Equally Efficient Transfection in Dividing and Growth-Arrested HeLa Cells
Pechan et al. Gene therapy for ischemic stroke
US8431119B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases